Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023

Apr 3, 2023 Press Releases

PDF Version AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrils AT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brain AT-07 (AT-04 + Brain Shuttle) demonstrated a 10-fold increase in brain penetration versus AT-04...

Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis

Dec 19, 2022 Press Releases

PDF Version SAN FRANCISCO – December 19, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the European Commission (EC) and European...

Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate

Oct 17, 2022 Press Releases

PDF Version SAN FRANCISCO, Calif. – October 17, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the first subject has been dosed in...

Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis

Sep 8, 2022 Press Releases

PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Organ-specific changes in...

Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis

Sep 7, 2022 Press Releases

PDF Version AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosis AT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer’s SAN FRANCISCO, Calif. – September 7, 2022 –...